Alexion Pharma (ALXN) Tops Q3 EPS by 6c; Guides Relativity In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Goldman Sachs Upgrades Alexion Pharmaceuticals (ALXN) to Buy
October 28, 2016 7:49 AM EDTGoldman Sachs upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Neutral to Buy with a price target of $158.00.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $131.37 yesterday.
... MoreFBR Capital Upgrades Alexion Pharmaceuticals (ALXN) to Market Perform
October 28, 2016 6:35 AM EDTFBR Capital upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Underperform to Market Perform with a price target of $130.00.
Analyst Christopher James commented, "Yesterday, Alexion reported its financial results for 3Q16. Total revenues came in at $799 million, well above our and the consensus estimates of $743 million and $787 million,... More
Alexion Pharma (ALXN) Commences Two ALXN1210 Phase 3s
October 27, 2016 6:32 AM EDTAlexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced the initiation of two Phase 3 trials of ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement. The first trial is a Phase 3 open-label, multinational, active-controlled study of ALXN1210 compared to eculizumab (Soliris®) in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion has also accelerated the initiation of a registration trial of ALXN1210 in patients with atypical hemolytic uremic syndrome (aHUS). This second trial is a Phase 3, open-label, single arm, multinational trial to evaluate the safety and efficacy of ALXN1210 in complement inhibitor... More
